Sagimet Biosciences Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

SGMT$10.89+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Cash Flows (unaudited)

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)


· · Three Months Ended March 31,
· · 2026 · · 2025
Cash flows from operating activities · · · ·
Net loss	$(10,650)	$(18,176)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on marketable securities, net	(140)	(535)
Non-cash operating lease expense	39	39
Stock-based compensation expense	1,839	1,472
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(297)	(687)
Accounts payable, accrued expenses and other current liabilities	637	3,390
Operating lease liabilities	(39)	(39)
Net cash used in operating activities	(8,611)	(14,536)
Cash flows from investing activities
Purchases of marketable securities	(6,752)	(15,575)
Sales and maturities of marketable securities	16,968	18,988
Net cash provided by investing activities	10,216	3,413
Net increase (decrease) in cash and cash equivalents	1,605	(11,123)
Cash and cash equivalents at beginning of period	35,021	75,840
Cash and cash equivalents at end of period	$36,626	$64,717

Supplemental non-cash investing and financing activities:
Deferred financing costs within accounts payable and accrued expenses	$32	$245

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.